Modeling anti-tumor Th1 and Th2 immunity in the rejection of melanoma

From MaRDI portal
Publication:1720105

DOI10.1016/j.jtbi.2010.04.030zbMath1461.92016OpenAlexW2020122130WikidataQ51699325 ScholiaQ51699325MaRDI QIDQ1720105

Raluca Eftimie, Jonathan L. Bramson, David J. D. Earn

Publication date: 12 February 2019

Published in: Journal of Theoretical Biology (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1016/j.jtbi.2010.04.030




Related Items (17)

Parameter estimation and sensitivity analysis for a model of tumor-immune interaction in the presence of immunotherapy and chemotherapyThe re-polarisation of M2 and M1 macrophages and its role on cancer outcomesModelling and investigation of the \(\mathrm{CD}4^+\) T cells -- macrophages paradox in melanoma immunotherapiesMathematical modelling for the role of CD\(4^+\)T cells in tumor-immune interactionsModeling pancreatic cancer dynamics with immunotherapyDynamics of tumor-\( \text{CD}4^+\)-cytokine-host cells interactions with treatmentsDynamic Analysis of the Melanoma Model: From Cancer Persistence to Its EradicationA model of tumor‐immune system interactions with healthy cells and immunotherapiesBifurcations and Chaotic Dynamics in a Tumour-Immune-Virus SystemMathematical modeling on helper T cells in a tumor immune systemA structural methodology for modeling immune-tumor interactions including pro- and anti-tumor factors for clinical applicationsMathematical models for immunology: current state of the art and future research directionsMathematical modeling of allergy and specific immunotherapy: Th1-Th2-Treg interactionsSpatial avascular growth of tumor in a homogeneous environmentPeriodically pulsed immunotherapy in a mathematical model of tumor, CD4\(^+\) T cells, and antitumor cytokine interactionsA mathematical model of tumor-immune interactions with an immune checkpoint inhibitorEffects of delay in a biological environment subject to tumor dynamics



Cites Work


This page was built for publication: Modeling anti-tumor Th1 and Th2 immunity in the rejection of melanoma